BACKGROUND & RATIONALE

The field of psychiatry has witnessed a paradigm shift towards personalized medicine, with pharmacogenetic (PGx) testing emerging as a promising tool to optimize pharmacotherapy outcomes. There is mounting evidence supporting the clinical utility of PGx-guided prescribing in psychiatry, particularly for antidepressant prescribing. The use of PGx testing results are facilitated by evidence-based dosing guidelines for antidepressants, antipsychotics, mood stabilizers/anticonvulsants, and atomoxetine. However, similar guidelines or practice standards to assist with deciding when and for whom psychiatric PGx testing should be offered are not available. much prefer the background that we included in our PGRN grant proposal. I have pasted in the relevant components. References will need to be incorporated. 

OBJECTIVES

The primary objective of this study is to build consensus for whom and when PGx testing should and should not be offered to patients with psychiatric diagnoses. The secondary objective is to identify gaps in the current evidence base informing PGx test use (i.e. indications and populations for which appropriateness of PGx is uncertain).